研究发现,一种GLP-1型药物,排出物在减慢帕金森病情发展速度方面是无效的。 Study finds exenatide, a GLP-1 drug, ineffective in slowing Parkinson's disease progression.

最近的一项研究发现,与Ozempic和Wegovy同一类的药物排出物,无助于减缓帕金森病情或改善症状。 A recent study found that exenatide, a drug in the same class as Ozempic and Wegovy, does not help slow Parkinson's disease or improve symptoms. 涉及194名病人的为期96周的试验显示,在运动、症状或脑部扫描方面没有任何好处。 The 96-week trial involving 194 patients showed no benefits in movement, symptoms, or brain scans. 尽管先前的实验室结果很有希望,但这项研究表明,虽然GLP-1药物对糖尿病和体重减退有效,但对于治疗帕金森氏病可能没有用处。 Despite earlier promising lab results, this study suggests that while GLP-1 drugs are effective for diabetes and weight loss, they may not be useful for treating Parkinson's.